The lowered full-year guidance signals that Q4 revenue may fall short of prior expectations, and the widening operating loss and cash burn suggest the company is still in an investment phase. Monitor Q4 results for progress toward cash flow breakeven and any updates on partner BLA approvals.
Price Chart
Executive Summary
ClearPoint Neuro reported Q3 2026 revenue of $12.1M (+36% YoY), in line with the $12.3M consensus, but GAAP EPS of -$0.24 missed the consensus estimate of -$0.32 (a beat of +25% on a per-share basis). The company lowered its full-year 2026 revenue guidance to $48M-$50M from the prior $52M-$56M range, implying a weaker Q4 outlook. Operating loss widened to $6.3M from $5.3M a year ago, and cash burn remains elevated at $20.1M YTD, partially offset by $22M in ATM equity proceeds.
Key Financial Metrics
Key Facts
- Q3 2026 revenue of $12.1M, up 36% YoY from $8.9M
- GAAP net loss per share of -$0.24 vs -$0.21 a year ago
- Full-year 2026 revenue guidance lowered to $48M-$50M from $52M-$56M
- Gross margin declined to 58% from 63% a year ago due to CAL overhead and intangible amortization
- Operating expenses grew 23% YoY to $13.4M
- Cash and equivalents of $46.2M, boosted by $22M net ATM proceeds
- Cash used in operations was $20.1M YTD vs $11.8M in the prior year period
- Neurosurgery navigation and therapy revenue grew 59% to $5.4M
- Biologics and drug delivery revenue grew 11% to $4.9M
- First BLA submitted by a partner for Huntington's Disease treatment
Financial Impact
Revenue guidance cut by $4M-$6M at the midpoint, implying a weaker Q4; operating cash burn accelerating
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Biologics and drug delivery | $4.9M | +11.0% |
| Neurosurgery navigation and therapy | $5.4M | +59.0% |
| Capital equipment and software | $1.7M | +68.0% |
Risk Factors
- Lowered revenue guidance implies a soft Q4 outlook
- Gross margin compression from CAL overhead and amortization
- Accelerating cash burn ($20.1M YTD) despite $22M ATM raise
- Dependence on partner drug approvals for long-term revenue growth
- High debt load ($50.8M notes payable) with PIK interest
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-436125 |
| Document: clpt-20261028.htm | 0001193125-26-436125 |
| Document: clpt-ex99_2.htm | 0001193125-26-436125 |
| Document: 0001193125-26-436125-index-headers.html | 0001193125-26-436125 |
| Document: 0001193125-26-436125-index.html | 0001193125-26-436125 |
| Document: 0001193125-26-436125.txt | 0001193125-26-436125 |
| 8-K Data (Synthetic) | 0001193125-26-436125 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 28, 2026 1d ago | 8-K | $10.56 | awaiting T+20 | awaiting T+20 | $10.69 (−1.23%) |
May 21, 2026 23w ago | 8-K | $11.44 $17.22 | ▲ +50.52% | ▲ +51.94% | $10.69 (−6.56%) |
May 20, 2026 23w ago | 144 | $11.70 $17.06 | ▲ +45.81% | ▲ +45.48% | $10.69 (−8.63%) |
May 13, 2026 24w ago | 8-K | $12.77 $13.44 | ▲ +5.25% | ▲ +6.10% | $10.69 (−16.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers